What question did this study set out to answer?

This study aims to explore mortality trends associated with lung cancer and cerebrovascular disease in the U.S. over a 20-year period.

February 2, 2026

Abstract TP186: Comorbid Lung Cancer and Cerebrovascular Disease-Associated Mortality Trends and Disparities in the United States From 1999 to 2019 – A CDC WONDER Database Analysis

Key Result

From 1999 to 2019, age-adjusted mortality rates for coexisting lung cancer and cerebrovascular disease decreased from 2.19 to 1.53 per 100,000, yet plateaued post-2014.

Key Points

This study aims to explore mortality trends associated with lung cancer and cerebrovascular disease in the U.S. over a 20-year period.
Analyzed mortality data from CDC WONDER database
Calculated age-adjusted mortality rates per 100,000 individuals aged > 25 years
Identified conditions using ICD-10 codes
Conducted trend analysis by year, sex, race/ethnicity, and region
Applied joinpoint regression for annual percent change calculation
Total of 76,797 deaths from coexisting lung cancer and cerebrovascular disease observed
Age-adjusted mortality rates decreased from 2.19 in 1999 to 1.53 in 2019
Men had higher mortality rates (2.14) compared to women (1.36)
Black or African American population exhibited the highest mortality rate (2.25)
Mortality trends plateaued post-2014, indicating a need for further healthcare interventions

Structured PICO

Population

Individuals aged > 25 years in the United States with coexisting lung cancer (ICD-10 C34) and cerebrovascular disease (ICD-10 I60-I69) from 1999 to 2019 (n=76,797 deaths).

Outcome

Age-adjusted mortality rates (AAMR) per 100,000 populationhard clinical

Mortality related to coexisting lung cancer and cerebrovascular disease in the US decreased from 1999 to 2014 but has plateaued since, with significant sociodemographic and geographic disparities persisting.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Introduction: Cancer and cerebrovascular disease (CeVD) are leading causes of death in developed countries, and lung cancer, the most commonly diagnosed cancer worldwide, is strongly associated with an increased risk of CeVD. The contemporary mortality trends related to these two conditions have not been thoroughly studied. This study explores the national mortality trends with concomitant lung cancer and CeVD from 1999 to 2019. This might help identify healthcare inequities and address them to control the disease burden. Methods: The mortality data was retrieved from the Centers for Disease Control and Prevention’s database, CDC WONDER, to extract age-adjusted mortality rates (AAMR) per 100,000 population from 1999 to 2019 among individuals aged > 25 years. Lung cancer was identified using ICD-10 code C34, and CeVD was identified using ICD-10 codes I60-I69. Those mortalities were included in the analysis where they were either the underlying or contributing cause of death. Trends were analyzed by year, sex, race/ethnicity, census region, and metropolitan status. Joinpoint regression was used to calculate the annual percent change (APC) in AAMR with 95% confidence intervals. Results: From 1999 to 2019, a total of 76,797 deaths occurred in patients with coexisting CeVD and lung cancer, with an overall AAMR of 1.69/100,000. The AAMR decreased from 2.19 in 1999 to 1.53 in 2019, showing a significantly decreasing trend from 1999 to 2014 (APC: -2.93, p < 0.001), followed by a stable trend from 2014 to 2019 (APC: 1.06, p = 0.06). Men had a higher AAMR (2.14) than women (1.36). The Black or African American population had the highest AAMR (2.25), followed by White (1.77), American Indian or Alaska Native (1.31), Asian or Pacific Islander (1.02), and Hispanic or Latino (0.70). Significant geographical variations were also observed, with the Midwest region (1.89) and the state of Alaska (2.59) having the highest AAMR. AAMR in nonmetropolitan areas (2.06) was higher compared to that in metropolitan (1.61) areas. Conclusion: The mortality trend related to coexisting lung cancer and CeVD decreased for most of the study period, but plateaued in the later years. The decline in mortality has leveled off since 2015, perhaps due to limited advances in prevention and continued sociodemographic health disparities highlighted by the study. This underscores the need for further research and targeted interventions.